Astrazeneca

AZNN

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Value held

$0k

Combined value at quarter end

Last quarter

0 bought

0 sold or trimmed

Price at Q4 ’25 end

$91.93

+19.8% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

+0.6%Q1 ’24

+15.1%Q2 ’24

-0.1%Q3 ’24

-15.9%Q4 ’24

+12.2%Q1 ’25

-4.9%Q2 ’25

+9.8%Q3 ’25

+19.8%Q4 ’25

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

2Q4 ’23

2Q1 ’24

2Q2 ’24

2Q3 ’24

2Q4 ’24

2Q1 ’25

2Q2 ’25

2Q3 ’25

3Q4 ’25

0Q1 ’26

0Q2 ’26

0Q3 ’26

Counts the managers on this site whose 13F for that quarter includes Astrazeneca.

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

No manager on this site held it in their latest 13F.

US-registered funds run by these managers that hold Astrazeneca, from their latest N-PORT filings.

Funds holding Astrazeneca

Polen International Growth FundPolen Capital Management	2.9%	$697k	31 Jul 2026
Oakmark International FundHarris Associates (Oakmark)	1.4%	$174m	30 Jun 2026
Oakmark Global FundHarris Associates (Oakmark)	1.3%	$14.4m	30 Jun 2026